The effect of docosahexaenoic acid on visual evoked potentials in a mouse model of Parkinson's disease: The role of cyclooxygenase-2 and nuclear factor kappa-B

Neurotoxicity Research

Volumn 20, Issue 3, 2011, Pages 250-262

  Ozsoy, Ozlem ^a   Tanriover, Gamze ^a   Derin, Narin ^a   Uysal, Nimet ^a   Demir, Necdet ^a   Gemici, Burcu ^a   Kencebay, Ceren ^a   Yargicoglu, Piraye ^a   Agar, Aysel ^a   Aslan, Mutay ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Cyclooxygenase 2; Docosahexaenoic acid; Nuclear factor kappa B; Parkinson's disease; Visual evoked potentials

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CASPASE 3; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; BRAIN LEVEL; BRAIN REGION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; EVOKED VISUAL RESPONSE; IMMUNOHISTOCHEMISTRY; LATENT PERIOD; MALE; MOTOR DYSFUNCTION; MOUSE; NERVE CELL NECROSIS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RETINA; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANALYSIS OF VARIANCE; ANIMALS; CASPASE 3; CYCLOOXYGENASE 2; DINOPROSTONE; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, VISUAL; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; NF-KAPPA B; RETINA; SUBSTANTIA NIGRA; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

MUS;

EID: 84855672002     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-011-9238-y     Document Type: Article

References (96)

1. Adams J (2001) Proteasome inhibition in cancer: Development of PS-341. Semin Oncol 28:613-619 (Pubitemid 33134421)
2. Araki T, Mizutani H, Matsubara M, Imai Y, Mizugaki M, Itoyama Y (2001) Nitric oxide synthase inhibitors cause motor deficits in mice. Eur Neuropsychopharmacol 11:125-133 (Pubitemid 32335556)
3. Barbato L, Rinalduzzi S, Laurenti M, Ruggieri S, Accornero N (1994) Color VEPs in Parkinson's disease. Electroencephalogr Clin Neurophysiol 92:169-172 (Pubitemid 24097610)
4. Barbeau A, Roy M, Bernier G, Campanella G, Paris S (1987) Ecogenetics of Parkinson's disease: Prevalence and environmental aspects in rural areas. Can J Neurol Sci 14:36-41 (Pubitemid 17022732)
5. Bazan NG (2009) Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection. Prostaglandins Leukot Essent Fatty Acids 81:205-211
6. Beal MF (2001) Experimental models of Parkinson's disease. Nat Rev Neurosci 2:325-334
7. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415-455
8. Bodis-Wollner I (1997) Visual electrophysiology in Parkinson's disease: PERG, VEP and visual P300. Clin Electroencephalogr 28:143-147 (Pubitemid 27311316)
9. Bodis-Wollner I, Onofrj M (1982) System diseases and visual evoked potential diagnosis in neurology: Changes due to synaptic malfunction. Ann N Y Acad Sci 388:327-348 (Pubitemid 13072899)
10. Bodis-Wollner I, Onofrj M (1987) The visual system in Parkinson's disease. Adv Neurol 45:323-327
11. Bodis-Wollner I, Yahr MD (1978) Measurements of visual evoked potentials in Parkinson's disease. Brain 101:661-671 (Pubitemid 9051163)
12. Bodis-Wollner I, Marx MS, Mitra S, Bobak P, Mylin L, Yahr M (1987) Visual dysfunction in Parkinson's disease. Loss in spatiotemporal contrast sensitivity. Brain 110(Pt 6):1675-1698
13. Boudrault C, Bazinet RP, Kang JX, Ma DW (2010) Cyclooxygenase- 2 and n-6 PUFA are lower and DHA is higher in the cortex of fat-1 mice. Neurochem Int 56:585-589
14. Bourre JM, Bonneil M, Clement M, Dumont O, Durand G, Lafont H, Nalbone G, Piciotti M (1993) Function of dietary polyunsaturated fatty acids in the nervous system. Prostaglandins Leukot Essent Fatty Acids 48:5-15 (Pubitemid 23011107)
15. Bousquet M, Saint-Pierre M, Julien C, Salem N Jr, Cicchetti F, Calon F (2008) Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease. Faseb J 22:1213-1225 (Pubitemid 351519975)
16. Boyd JD, Jang H, Shepherd KR, Faherty C, Slack S, Jiao Y, Smeyne RJ (2007) Response to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta. Brain Res 1175:107-116 (Pubitemid 47513006)
17. Bulens C, Meerwaldt JD, Van der Wildt GJ, Van Deursen JB (1987) Effect of levodopa treatment on contrast sensitivity in Parkinson's disease. Ann Neurol 22:365-369 (Pubitemid 17137900)
18. Buttner T, Kuhn W, Muller T, Heinze T, Puhl C, Przuntek H (1996) Chromatic and achromatic visual evoked potentials in Parkinson's disease. Electroencephalogr Clin Neurophysiol 100: 443-447
19. Buttner T, Muller T, Kuhn W (2000) Effects of apomorphine on visual functions in Parkinson's disease. J Neural Transm 107:87-94 (Pubitemid 30077045)
20. Cansev M, Ulus IH, Wang L, Maher TJ, Wurtman RJ (2008) Restorative effects of uridine plus docosahexaenoic acid in a rat model of Parkinson's disease. Neurosci Res 62:206-209
21. Carlton PS, Gopalakrishnan R, Gupta A, Liston BW, Habib S, Morse MA, Stoner GD (2002) Piroxicam is an ineffective inhibitor of N- nitrosomethylbenzylamine-induced tumorigenesis in the rat esophagus. Cancer Res 62:4376-4382 (Pubitemid 34827296)
22. Catalan J, Moriguchi T, Slotnick B, Murthy M, Greiner RS, Salem N Jr (2002) Cognitive deficits in docosahexaenoic acid-deficient rats. Behav Neurosci 116:1022-1031 (Pubitemid 35429637)
23. Chipuk JE, Bouchier-Hayes L, Green DR (2006) Mitochondrial outer membrane permeabilization during apoptosis: The innocent bystander scenario. Cell Death Differ 13:1396-1402 (Pubitemid 44057475)
24. Cudeiro J, Rivadulla C (1999) Sight and insight-on the physiological role of nitric oxide in the visual system. Trends Neurosci 22:109-116 (Pubitemid 29151803)
25. de Meira Santos Lima M, Braga Reksidler A, Marques Zanata S, Bueno Machado H, Tufik S, Vital MA (2006) Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats. Brain Res 1101:117-125 (Pubitemid 44036768)
26. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52:381-389 (Pubitemid 19037600)
27. Disshon KA, Dluzen DE (1997) Estrogen as a neuromodulator of MPTP-induced neurotoxicity: Effects upon striatal dopamine release. Brain Res 764:9-16 (Pubitemid 27380635)
28. Dyer RS, Howell WE, MacPhail RC (1981) Dopamine depletion slows retinal transmission. Exp Neurol 71:326-340 (Pubitemid 11179630)
29. Feng Z, Li D, Fung PC, Pei Z, Ramsden DB, Ho SL (2003) COX-2- deficient mice are less prone to MPTP-neurotoxicity than wildtype mice. Neuroreport 14:1927-1929 (Pubitemid 38339762)
30. Galli C, White HB Jr, Paoletti R (1971) Lipid alterations and their reversion in the central nervous system of growing rats deficient in essential fatty acids. Lipids 6:378-387
31. Gasser T (2001) Molecular genetics of Parkinson's disease. Adv Neurol 86:23-32
32. Gawel MJ, Das P, Vincent S, Rose FC (1981) Visual and auditory evoked responses in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 44:227-232 (Pubitemid 11113197)
33. Gemici B, Tan R, Ongut G, Izgut-Uysal VN (2010) Expressions of inducible nitric oxide synthase and cyclooxygenase-2 in gastric ischemia-reperfusion: Role of angiotensin II. J Surg Res 161:126-133
34. Gerlach M, Riederer P (1996) Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987-1041 (Pubitemid 26383833)
35. German OL, Insua MF, Gentili C, Rotstein NP, Politi LE (2006) Docosahexaenoic acid prevents apoptosis of retina photoreceptors by activating the ERK/MAPK pathway. J Neurochem 98:1507-1520 (Pubitemid 44200442)
36. Ghilardi MF, Bodis-Wollner I, Onofrj MC, Marx MS, Glover AA (1988a) Spatial frequency-dependent abnormalities of the pattern electroretinogram and visual evoked potentials in a parkinsonian monkey model. Brain 111(Pt 1):131-149
37. Ghilardi MF, Chung E, Bodis-Wollner I, Dvorzniak M, Glover A, Onofrj M (1988b) Systemic 1-methyl,4-phenyl,1-2-3-6-tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates. Life Sci 43:255-262
38. Ghosh A, Roy A, Liu X, Kordower JH, Mufson EJ, Hartley DM, Ghosh S, Mosley RL, Gendelman HE, Pahan K (2007) Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 104:18754-18759 (Pubitemid 350210769)
39. Ghosh A, Roy A, Matras J, Brahmachari S, Gendelman HE, Pahan K (2009) Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci 29:13543-13556
40. Green P, Glozman S, Yavin E (2001) Ethyl docosahexaenoateassociated decrease in fetal brain lipid peroxide production is mediated by activation of prostanoid and nitric oxide pathways. Biochim Biophys Acta 1531:156-164 (Pubitemid 32241258)
41. Hacioglu G, Agar A, Yargicoglu P (2006) The role of docosahexaenoic acid on visual evoked potentials in one kidney-one clip hypertension. Acta Ophthalmol Scand 84:488-494 (Pubitemid 44102845)
42. Hacioglu G, Kose O, Aslan M, Agar A (2007) Beneficial effects of docosahexaenoic acid on active avoidance performance in 1K- 1C hypertensive rats. Neurobiol Learn Mem 87:159-165 (Pubitemid 44667578)
43. Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 59:1609-1623
44. Haobam R, Sindhu KM, Chandra G, Mohanakumar KP (2005) Swimtest as a function of motor impairment in MPTP model of Parkinson's disease: A comparative study in two mouse strains. Behav Brain Res 163:159-167 (Pubitemid 41138049)
45. Harnois C, Di Paolo T (1990) Decreased dopamine in the retinas of patients with Parkinson's disease. Invest Ophthalmol Vis Sci 31:2473-2475
46. Hetzler BE, Boyes WK, Creason JP, Dyer RS (1988) Temperaturedependent changes in visual evoked potentials of rats. Electroencephalogr Clin Neurophysiol 70:137-154
47. Hoang T, Choi DK, Nagai M, Wu DC, Nagata T, Prou D, Wilson GL, Vila M, Jackson-Lewis V, Dawson VL, Dawson TM, Chesselet MF, Przedborski S (2009) Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease. Free Radic Biol Med 47:1049-1056
48. Hunot S, Vila M, Teismann P, Davis RJ, Hirsch EC, Przedborski S, Rakic P, Flavell RA (2004) JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 101:665-670 (Pubitemid 38084694)
49. Kabuto H, Amakawa M, Mankura M, Yamanushi TT, Mori A (2009) Docosahexaenoic acid ethyl ester enhances 6-hydroxydopamineinduced neuronal damage by induction of lipid peroxidation in mouse striatum. Neurochem Res 34:1299-1303
50. Kang JM, Park HJ, Choi YG, Choe IH, Park JH, Kim YS, Lim S (2007) Acupuncture inhibits microglial activation and inflammatory events in the MPTP-induced mouse model. Brain Res 1131:211-219 (Pubitemid 46053895)
51. Kato H, Kurosaki R, Oki C, Araki T (2004) Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice. Brain Res 1030:66-73 (Pubitemid 39563827)
52. Kidd PM (2000) Parkinson's disease as multifactorial oxidative neurodegeneration: Implications for integrative management. Altern Med Rev 5:502-529 (Pubitemid 32104062)
53. Kobayashi T, Araki T, Itoyama Y, Takeshita M, Ohta T, Oshima Y (1997) Effects of L-dopa and bromocriptine on haloperidolinduced motor deficits in mice. Life Sci 61:2529-2538 (Pubitemid 28035577)
54. Kremer JM, Lawrence DA, Jubiz W, DiGiacomo R, Rynes R, Bartholomew LE, Sherman M (1990) Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects. Arthritis Rheum 33:810-820 (Pubitemid 20205760)
55. Langheinrich T, Tebartz van Elst L, Lagreze WA, Bach M, Lucking CH, Greenlee MW (2000) Visual contrast response functions in Parkinson's disease: Evidence from electroretinograms, visually evoked potentials and psychophysics. Clin Neurophysiol 111:66-74
56. Lee JA, Song HY, Ju SM, Lee SJ, Kwon HJ, Eum WS, Jang SH, Choi SY, Park JS (2009a) Differential regulation of inducible nitric oxide synthase and cyclooxygenase-2 expression by superoxide dismutase in lipopolysaccharide stimulated RAW 264.7 cells. Exp Mol Med 41:629-637
57. Lee SA, Kim HJ, Chang KC, Baek JC, Park JK, Shin JK, Choi WJ, Lee JH, Paik WY (2009b) DHA and EPA down-regulate COX-2 expression through suppression of NF-kappaB activity in LPStreated human umbilical vein endothelial cells. Korean J Physiol Pharmacol 13:301-307
58. Levant B, Ozias MK, Carlson SE (2007) Specific brain regions of female rats are differentially depleted of docosahexaenoic acid by reproductive activity and an (n-3) fatty acid-deficient diet. J Nutr 137:130-134 (Pubitemid 46052870)
59. Lockwood AH (2000) Pesticides and parkinsonism: Is there an etiological link? Curr Opin Neurol 13:687-690 (Pubitemid 32002653)
60. Matsui H, Udaka F, Tamura A, Oda M, Kubori T, Nishinaka K, Kameyama M (2005) The relation between visual hallucinations and visual evoked potential in Parkinson disease. Clin Neuropharmacol 28:79-82 (Pubitemid 40471881)
61. Mattammal MB, Strong R, Lakshmi VM, Chung HD, Stephenson AH (1995) Prostaglandin H synthetase-mediated metabolism of dopamine: Implication for Parkinson's disease. J Neurochem 64:1645-1654
62. McLaughlin P, Zhou Y, Ma T, Liu J, Zhang W, Hong JS, Kovacs M, Zhang J (2006) Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity. Glia 53: 567-582
63. Meissner W, Hill MP, Tison F, Gross CE, Bezard E (2004) Neuroprotective strategies for Parkinson's disease: Conceptual limits of animal models and clinical trials. Trends Pharmacol Sci 25:249-253 (Pubitemid 38553826)
64. Michael-Titus AT (2007) Omega-3 fatty acids and neurological injury. Prostaglandins Leukot Essent Fatty Acids 77:295-300 (Pubitemid 350198867)
65. Mills RD, Sim CH, Mok SS, Mulhern TD, Culvenor JG, Cheng HC (2008) Biochemical aspects of the neuroprotective mechanism of PTEN-induced kinase-1 (PINK1). J Neurochem 105:18-33 (Pubitemid 351441646)
66. Mitra N, Mohanakumar KP, Ganguly DK (1992) Dissociation of serotoninergic and dopaminergic components in acute effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in mice. Brain Res Bull 28:355-364
67. Murthy M, Hamilton J, Greiner RS, Moriguchi T, Salem N Jr, Kim HY (2002) Differential effects of n-3 fatty acid deficiency on phospholipid molecular species composition in the rat hippocampus. J Lipid Res 43:611-617
68. Nicklas WJ, Vyas I, Heikkila RE (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 36:2503-2508 (Pubitemid 15072756)
69. Ogawa N, Mizukawa K, Hirose Y, Kajita S, Ohara S, Watanabe Y (1987) MPTP-induced parkinsonian model in mice: Biochemistry, pharmacology and behavior. Eur Neurol 26(Suppl 1):16-23 (Pubitemid 17047054)
70. Onofrj M, Bodis-Wollner I (1982) Dopaminergic deficiency causes delayed visual evoked potentials in rats. Ann Neurol 11:484-490 (Pubitemid 12158809)
71. Onofrj M, Ghilardi MF, Basciani M, Gambi D (1986) Visual evoked potentials in parkinsonism and dopamine blockade reveal a stimulus-dependent dopamine function in humans. J Neurol Neurosurg Psychiatry 49:1150-1159
72. Pawlosky RJ, Bacher J, Salem N Jr (2001) Ethanol consumption alters electroretinograms and depletes neural tissues of docosahexaenoic acid in rhesus monkeys: Nutritional consequences of a low n-3 fatty acid diet. Alcohol Clin Exp Res 25:1758-1765 (Pubitemid 34033146)
73. Peachey NS, Ball SL (2003) Electrophysiological analysis of visual function in mutant mice. Doc Ophthalmol 107:13-36 (Pubitemid 36896235)
74. Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, Miller R, Akram M (2001) The parkinsonian toxin 1-methyl-4- phenyl-1,2,3,6- tetrahydropyridine (MPTP): A technical review of its utility and safety. J Neurochem 76:1265-1274 (Pubitemid 32198231)
75. Przybylkowski A, Kurkowska-Jastrzebska I, Joniec I, Ciesielska A, Czlonkowska A, Czlonkowski A (2004) Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson's disease induced by 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine administration to mouse. Brain Res 1019:144-151 (Pubitemid 39078620)
76. Puskas LG, Bereczki E, Santha M, Vigh L, Csanadi G, Spener F, Ferdinandy P, Onochy A, Kitajka K (2004) Cholesterol and cholesterol plus DHA diet-induced gene expression and fatty acid changes in mouse eye and brain. Biochimie 86:817-824 (Pubitemid 39602761)
77. Reksidler AB, Lima MM, Zanata SM, Machado HB, da Cunha C, Andreatini R, Tufik S, Vital MA (2007) The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. Eur J Pharmacol 560:163-175 (Pubitemid 46341312)
78. Sakamoto T, Cansev M, Wurtman RJ (2007) Oral supplementation with docosahexaenoic acid and uridine-50-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res 1182:50-59 (Pubitemid 350086992)
79. Samadi P, Gregoire L, Rouillard C, Bedard PJ, Di Paolo T, Levesque D (2006) Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Ann Neurol 59:282-288 (Pubitemid 43202481)
80. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54:823-827
81. Schmidt N, Ferger B (2001) Neurochemical findings in the MPTP model of Parkinson's disease. J Neural Transm 108:1263-1282 (Pubitemid 33141302)
82. Schober A (2004) Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 318:215-224 (Pubitemid 39366054)
83. Sedelis M, Schwarting RK, Huston JP (2001) Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 125:109-125 (Pubitemid 33000449)
84. Simopoulos AP (1989) Summary of the NATO advanced research workshop on dietary omega 3 and omega 6 fatty acids: Biological effects and nutritional essentiality. J Nutr 119:521-528
85. Singh J, Hamid R, Reddy BS (1997) Dietary fat and colon cancer: Modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis. Cancer Res 57:3465-3470 (Pubitemid 27355493)
86. Strain GM, Tedford BL (1993) Flash and pattern reversal visual evoked potentials in C57BL/6J and B6CBAF1/J mice. Brain Res Bull 32:57-63 (Pubitemid 23160581)
87. Tanriover G, Seval-Celik Y, Ozsoy O, Akkoyunlu G, Savcioglu F, Hacioglu G, Demir N, Agar A (2010) The effects of docosahexaenoic acid on GDNF and NTN in bilateral rat model of Parkinson's disease. Folia Histochem Cytobiol 48:434-441
88. Teismann P, Vila M, Choi DK, Tieu K, Wu DC, Jackson-Lewis V, Przedborski S (2003) COX-2 and neurodegeneration in Parkinson's disease. Ann N Y Acad Sci 991:272-277 (Pubitemid 36793820)
89. Temma K, Shimoya K, Zhang Q, Kimura T, Wasada K, Kanzaki T, Azuma C, Koyama M, Murata Y (2004) Effects of 4-hydroxy-2- nonenal, a marker of oxidative stress, on the cyclooxygenase-2 of human placenta in chorioamnionitis. Mol Hum Reprod 10:167-171 (Pubitemid 38456018)
90. Uauy R, Hoffman DR, Peirano P, Birch DG, Birch EE (2001) Essential fatty acids in visual and brain development. Lipids 36:885-895 (Pubitemid 33065189)
91. Vijitruth R, Liu M, Choi DY, Nguyen XV, Hunter RL, Bing G (2006) Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J Neuroinflamm 3:6
92. Wallace DC (2005) A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. Annu Rev Genet 39:359-407 (Pubitemid 43011120)
93. Wang T, Pei Z, Zhang W, Liu B, Langenbach R, Lee C, Wilson B, Reece JM, Miller DS, Hong JS (2005) MPP?-induced COX-2 activation and subsequent dopaminergic neurodegeneration. Faseb J 19:1134-1136 (Pubitemid 40946442)
94. Weisinger HS, Vingrys AJ, Bui BV, Sinclair AJ (1999) Effects of dietary n-3 fatty acid deficiency and repletion in the guinea pig retina. Invest Ophthalmol Vis Sci 40:327-338 (Pubitemid 29063828)
95. Wurtman RJ, Ulus IH, Cansev M, Watkins CJ, Wang L, Marzloff G (2006) Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally. Brain Res 1088:83-92 (Pubitemid 43729416)
96. Yao H, Tang X, Shao X, Feng L, Wu N, Yao K (2007) Parthenolide protects human lens epithelial cells from oxidative stressinduced apoptosis via inhibition of activation of caspase-3 and caspase-9. Cell Res 17:565-571 (Pubitemid 46980953)